Bioheart to Present at the PRP and Regenerative Medicine Symposium (TOBI 2014)
04 June 2014 - 10:00PM
Marketwired
Bioheart to Present at the PRP and Regenerative Medicine Symposium
(TOBI 2014)
SUNRISE, FL--(Marketwired - Jun 4, 2014) - Bioheart, Inc.
(OTCQB: BHRT), a biotechnology company focused on the discovery,
development and commercialization of autologous cell therapies,
announced that it will present at the 5th annual PRP &
Regenerative Medicine Symposium on June 6-7 (TOBI 2014). The
Orthobiologic Institute (TOBI) was established to share best
practices in the cutting-edge field of Platelet Rich Plasma (PRP)
and regenerative medicine therapies. The Orthobiologic Institute's
live events are known for their global draw and opportunity to
connect with physicians in this rapidly growing field with
intensive hands-on programs. Kristin Comella, Bioheart's Chief
Scientific Officer, will present data from cardiac and orthopedic
studies.
About Bioheart, Inc. Bioheart, Inc. is committed to maintaining
its leading position within the cardiovascular sector of the cell
technology industry delivering cell therapies and biologics that
help address congestive heart failure, lower limb ischemia, chronic
heart ischemia, acute myocardial infarctions and other issues.
Bioheart's goals are to cause damaged tissue to be regenerated,
when possible, and to improve a patient's quality of life and
reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery,
development and, subject to regulatory approval, commercialization
of autologous cell therapies for the treatment of chronic and acute
heart damage and peripheral vascular disease. Its leading product,
MyoCell, is a clinical muscle-derived cell therapy designed to
populate regions of scar tissue within a patient's heart with new
living cells for the purpose of improving cardiac function in
chronic heart failure patients. For more information on Bioheart,
visit www.bioheartinc.com, or visit us on Facebook: Bioheart and
Twitter @BioheartInc.
Forward-Looking Statements: Except for historical matters
contained herein, statements made in this press release are
forward-looking statements. Without limiting the generality of the
foregoing, words such as "may," "will," "to," "plan," "expect,"
"believe," "anticipate," "intend," "could," "would," "estimate," or
"continue" or the negative other variations thereof or comparable
terminology are intended to identify forward-looking
statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Also, forward-looking statements
represent our management's beliefs and assumptions only as of the
date hereof. Except as required by law, we assume no obligation to
update these forward-looking statements publicly, or to update the
reasons actual results could differ materially from those
anticipated in these forward-looking statements, even if new
information becomes available in the future.
The Company is subject to the risks and uncertainties described
in its filings with the Securities and Exchange Commission,
including the section entitled "Risk Factors" in its Annual Report
on Form 10-K for the year ended December 31, 2013, and its
Quarterly Report on Form 10-Q for the quarter ended March 31,
2014.
Media Contact: Carissa Matton Bioheart, Inc. 13794 NW 4th
Street, Suite 212 Sunrise, Florida 33325 Phone: 772.285.8511
cmatton@bioheartinc.com
US Stem Cell (CE) (USOTC:USRM)
Historical Stock Chart
From Oct 2024 to Nov 2024
US Stem Cell (CE) (USOTC:USRM)
Historical Stock Chart
From Nov 2023 to Nov 2024
